Dec 01, 2022 / 06:00PM GMT
Umer Raffat - Evercore ISI - Analyst
Excellent. Thank you guys for joining us. Pleasure to have Kronos management join us. Many of you may obviously know and remember Norbert over the years discussing many things at Gilead. But today, this is about a new platform and new molecules. So there's a lot to discuss.
Let me turn over to you, Norbert.
Norbert Bischofberger - Kronos Bio, Inc. - President & CEO
Yes. Umer, thank you, and Evercore, for having us. It's a great pleasure to participate in this fireside chat.
Questions and Answers:
Umer Raffat - Evercore ISI - AnalystOutstanding. So Norbert, there's obviously two key programs, and we're going to jump right in. And there's newer stuff which is approaching IND enabling as well. Where do you guys get the most questions? And which one has the first, perhaps, upcoming data readout? Maybe we should start there.
Norbert Bischofberger - Kronos Bio, Inc. - President & CEO
The two programs -- the two
Trustpilot
